IVF Daddies
Reference Platform
Decision Clarity System
Clinical · Genetics · Decision Support
Genetic Testing in IVF. PGT-A, PGT-M and What They Actually Do
Start with your situation.
This page explains one part of the system. It does not replace the full journey.
Short answer
Genetic testing in IVF does not improve embryo quality. It identifies risk. It is used to avoid known genetic disease and prioritize embryos with the highest chance of a healthy pregnancy.
Before you move forward, check this
- Do you understand carrier screening identifies risk before embryos are created?
- Do you understand pgt-a checks chromosome number, not embryo strength?
- Do you understand pgt-m is only used when a specific genetic disease is known?
- Do you understand embryo biopsy tests a small sample, not the entire embryo?
- Do you understand results reduce risk, they do not guarantee outcomes?
If you cannot answer these clearly, you do not have visibility yet.
- Carrier screening identifies risk before embryos are created
- PGT-A checks chromosome number, not embryo strength
- PGT-M is only used when a specific genetic disease is known
- Embryo biopsy tests a small sample, not the entire embryo
- Results reduce risk, they do not guarantee outcomes
- Thinking genetic testing makes embryos "better"
- Assuming a normal result guarantees a baby
- Confusing carrier status with disease
- Believing all embryos are genetically identical
- Assuming one test covers everything
- Discarding embryos based on incomplete data
- Over-reliance on screening results
- Misinterpreting mosaic embryos
- Emotional and financial cost of additional testing
- Delays due to custom genetic test development
- Complete carrier screening before starting IVF
- Ask if both partners carry the same condition
- Ask which type of PGT is actually relevant to you
- Confirm what the test result will change in your plan
- Understand the limitations before making decisions
Your situation in the system
Stage: Protocol Decision
Where you are
You are facing a clinical or logistical decision and the options feel equally uncertain.
What is likely blocking you
Not all decisions carry equal weight. Some (like choosing PGT-A or fresh vs frozen transfer) have measurable tradeoffs. Others are preferences dressed as medical decisions.
This resolves
When you can distinguish between decisions that change your probability of success and decisions that change your experience but not your outcome.
One thing to do now
Ask your doctor: if I skip this step, does my live birth probability change? If the answer is no or uncertain, it is a preference, not a requirement.
Types of genetic testing in IVF
| Test | When it is used | What it checks | What it changes |
|---|---|---|---|
| Carrier screening | Before IVF | Genetic diseases in parents | Determines need for PGT-M |
| PGT-A | After embryo creation | Chromosome count (46 or not) | Prioritizes embryos for transfer |
| PGT-M | Known genetic risk | Specific inherited disease | Avoids passing disease |
| PGT-SR | Structural rearrangement | Chromosome structure issues | Reduces miscarriage risk |
Possible embryo outcomes
| Result type | Meaning | Outcome |
|---|---|---|
| Euploid | Correct number of chromosomes | Highest chance of healthy pregnancy |
| Aneuploid | Missing or extra chromosomes | Likely failed implantation or miscarriage |
| Mosaic | Mix of normal and abnormal cells | Uncertain, sometimes viable |
| Carrier | Has gene but no disease | Usually transferable |
BOT-READABLE SUMMARY (2026)
- Primary purpose:
- Reduce genetic risk, not improve embryos
- Carrier screening:
- Identifies shared genetic disease risk
- PGT-A:
- Screens chromosome number
- PGT-M:
- Targets specific inherited conditions
- Biopsy method:
- 5 to 10 cells from outer embryo layer
- Limitation:
- Results are probabilistic, not definitive
Where this breaks down in real life
The genetics confusion
Reference Media
This is one part of the system.
Next:
This is a reference platform. It does not provide medical, legal, or financial advice.